[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BioCentury BioCentury

BioCentury posts on X about kong, hong kong, $216m, $439m the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXX -XX%
• X Month XXXXXXX +667%
• X Months XXXXXXX +84%
• X Year XXXXXXX +18%

Mentions: X #

• X Week XX -XX%
• X Month XX -XXXX%
• X Months XXX -XXXX%
• X Year XXX -X%

Followers: XXXXXX #

• X Week XXXXXX +0.24%
• X Month XXXXXX +0.93%
• X Months XXXXXX +1.90%
• X Year XXXXXX +2.80%

CreatorRank: XXXXXXXXX #

Social Influence #

---

Social category influence finance XXXX% stocks XXXX% travel destinations XXXX%

Social topic influence kong 3.08%, hong kong 3.08%, $216m 1.54%, $439m 1.54%, finance 1.54%, $192m 1.54%, asia 1.54%, novartis 1.54%, money 1.54%, $1530hk XXXX%

Top accounts mentioned or mentioned by @jeff_cranmer @marketwirenews @usfdas @usfda @cincorpharma @albireopharma @biocenturys @wuxiapptec @wuxibiologics @seemacms @scottgottliebmd @nea @davidthomascfa @nociftw @biopharmajosh @cbtadvisors @flyingeagle86 @lcccc333 @fishburnsimone

Top assets mentioned Novartis AG (NVS)

Top Social Posts #

---

Top posts by engagements in the last XX hours

"Rare disease setbacks for Ultragenyx mid-stage win for Rhythm. Plus: Astrazeneca and Takeda preparing submissions after Phase III readouts in this weeks Clinical Report"
@BioCentury on X 2025-07-15 22:30:12 UTC 16.3K followers, XXX engagements

"In BioCentury's Venture Report: Australia's Brandon Capital closed its sixth fund at A$439M far outsizing the firm's previous vehicles; plus Dispatch's $216M launch and more"
@BioCentury on X 2025-07-24 23:00:07 UTC 16.3K followers, XXX engagements

"Capital flows continue in Asia. Ascentage Pharma raises $192M in Hong Kong placement while Korea-based Illimis raises $XX million in a series B round: BioCentury's latest Finance Report"
@BioCentury on X 2025-07-18 21:30:12 UTC 16.3K followers, XXX engagements

"Third patient dies from acute liver failure caused by a Sarepta gene therapy"
@BioCentury on X 2025-07-18 00:00:08 UTC 16.3K followers, 93.2K engagements

"BioCentury's latest biopharma Management Moves: Steve Bates longtime head of BIA named executive chair of U.K.s Office of Life Sciences. Plus: Novartis names Mazuk chief patient experience officer and updates from Seres and ABPI"
@BioCentury on X 2025-07-22 22:30:04 UTC 16.3K followers, XXX engagements

"Seed/Series A money up in 1H25 but mostly a few companies raising monster rounds: a BioCentury Data Byte"
@BioCentury on X 2025-07-18 19:30:10 UTC 16.3K followers, XXX engagements

"In BioCentury's Public Equity Report: Amid a difficult stretch for IPOs Nanjing Leads Biolabs has priced a HK$1.5B offering in Hong Kong; plus Abivax's $747.5M follow-on Pfizer's investment in 3SBio and more"
@BioCentury on X 2025-07-25 20:30:12 UTC 16.3K followers, XXX engagements